Second-Line Therapy for Endometrial Cancer: The Need for Better Options

A 60-year-old normal-weight woman had been diagnosed with stage IIIA, grade 3, estrogen receptor (ER)-positive progesterone receptor (PgR)-positive endometrioid endometrial cancer. She received six cycles of adjuvant carboplatin and paclitaxel. Adjuvant radiotherapy was not given because she had a history of rectal adenocarcinoma 9 years ago treated with radiation plus fluorouracil followed by 12 cycles of infusional fluorouracil, leucovorin, and oxaliplatin chemotherapy. Six months later, she relapsed with multiple lung nodules, a 4.5-cm pelvic mass, and multiple mesenteric masses. Her past medical history was otherwise notable for several small strokes 8 years prior with no residual deficit; she was not currently receiving anticoagulants. She had no symptoms from her cancer except mild vaginal spotting, but she did have persistent peripheral neuropathy, for which she was taking gabapentin. She presented to discuss treatment options for her recurrent endometrial cancer.